- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07947147
Thread Embedding Acupuncture Added to Antihistamine Treatment for Chronic Urticaria
Evaluation of the Efficacy and Safety of Thread Embedding Acupuncture Combined With an H1 Antihistamine for the Treatment of Chronic Urticaria
This study will test whether adding thread embedding acupuncture to an antihistamine helps adults with chronic hives whose symptoms remain bothersome despite taking the antihistamine. In thread embedding acupuncture, a clinician uses a needle to place a small dissolvable thread at an acupuncture point. The comparison procedure uses the same acupuncture points and a needle, without placing a thread. Both groups take cetirizine.
The researchers plan to enroll 124 adults at three hospitals in Ho Chi Minh City, Vietnam. Participants will be assigned by chance to one of the two groups. They will receive two procedures, two weeks apart. Participants and the people who assess their symptoms will not know which procedure they received. The main assessment compares changes in hives and itching after four weeks. The study will also assess quality of life, a blood marker called total immunoglobulin E, additional antihistamine use, side effects, and whether symptoms return during follow-up through week 8.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
This multicenter, randomized, sham-controlled, parallel-group trial compares polydioxanone (PDO) thread embedding acupuncture plus cetirizine with sham thread embedding acupuncture plus cetirizine. Eligible adults will complete a 7-day run-in with oral cetirizine 10 mg daily and a daily hives and itch diary. Participants with a 7-day Urticaria Activity Score (UAS7) of at least 16 and a weekly itch score of at least 8 after run-in are eligible for randomization.
The trial plans to randomize 124 participants in a 1:1 ratio using concealed block randomization through REDCap. Participants and outcome assessors are masked to allocation. The statistician will analyze coded groups. Clinicians performing the procedure know the assignment. Procedures are scheduled at baseline and week 2, with a 4-week treatment period and a further 4 weeks of follow-up. The primary analysis compares change from baseline in UAS7 at week 4. Other assessments include UAS7 at weeks 2 and 8, urticaria-related quality of life, serum total IgE, rescue medication use, adverse events, and symptom recurrence. Analyses are planned on an intention-to-treat basis.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Sang Thanh Do, MD, MSc
- Telefonnummer: +84 948 561 030
- E-mail: dtsang@ump.edu.vn
Studiesteder
-
-
-
Ho Chi Minh City, Vietnam
- Ho Chi Minh City Traditional Medicine Hospital, Outpatient Department
-
Ho Chi Minh City, Vietnam
- Le Van Thinh Hospital, Department of Dermatology
-
Ho Chi Minh City, Vietnam
- University Medical Center Ho Chi Minh City, Branch 3
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 18 years or older and willing to provide written informed consent.
- Chronic urticaria diagnosed according to the EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline. Transient wheals and itching occur at least daily for more than 6 weeks despite prior or current use of an H1 antihistamine, without serious systemic symptoms. Individual wheals resolve within 30 minutes to 24 hours.
- UAS7 of at least 16 and weekly itch score of at least 8 after the 7-day run-in.
- No previous thread embedding acupuncture.
Exclusion Criteria:
- Urticaria with an identified cause, including physical or mechanical urticaria.
- Warning signs of systemic or autoinflammatory disease (e.g., Schnitzler syndrome or cryopyrin-associated periodic syndromes), or urticarial vasculitis.
- Cutaneous mast cell disease or erythema multiforme.
- Current or prior severe associated symptoms such as laryngeal edema, acute angioedema, anaphylaxis, or bradykinin-mediated angioedema including hereditary angioedema.
- Other chronic pruritic skin disease that could interfere with assessment.
- History of allergy to implant materials, especially absorbable suture or catgut, or a predisposition to keloid formation.
- Current or recent immunosuppressive therapy or systemic corticosteroids within 2 to 4 weeks (or 30 days) before participation, as specified in the protocol.
- Biologics such as omalizumab, leukotriene receptor antagonists, or H2 antihistamines within 7 to 14 days before screening or randomization, as specified in the protocol.
- H1 antihistamine use above the recommended dose within 3 days before screening.
- Psychotropic medication within the preceding month.
- Malignancy or severe endocrine disorder.
- Serious cardiovascular or cerebrovascular disease, diabetes mellitus, severe hepatic or renal failure, or a hematopoietic disorder.
- Severe debilitation with reduced immune resistance.
- Other serious systemic autoimmune disease, such as systemic lupus erythematosus.
- Cognitive impairment, psychiatric illness, or a communication barrier that prevents participation in the treatment procedures.
- A nonabsorbable implant at the intended procedure site.
- Pregnancy, breastfeeding, or plans to become pregnant during the study.
- Participation in another clinical trial in the preceding 3 months.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: PDO Thread Embedding Acupuncture Plus Cetirizine
Participants receive polydioxanone (PDO) thread embedding acupuncture at baseline and week 2, plus oral cetirizine as background treatment. |
An absorbable monofilament polydioxanone (PDO) thread is implanted at seven bilateral acupuncture points (14 sites) at baseline and week 2. Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded. |
|
Sham-komparator: Sham Thread Embedding Acupuncture Plus Cetirizine
Participants receive a sham procedure at the same acupuncture points at baseline and week 2. The clinician uses an empty needle, so no thread is implanted. Participants also receive oral cetirizine as background treatment. |
Both arms receive cetirizine 10 mg orally each morning during the 7-day run-in and 4-week treatment period. Additional cetirizine use for rescue is recorded. The clinician inserts and withdraws an empty needle at the same acupuncture points at baseline and week 2. The procedure leaves no implanted thread. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in 7-Day Urticaria Activity Score (UAS7) at Week 4
Tidsramme: Baseline and week 4
|
UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline. |
Baseline and week 4
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in UAS7 at Weeks 2 and 8
Tidsramme: Baseline and weeks 2 and 8
|
UAS7 is the sum of participant-reported daily hive and itch severity scores over seven consecutive days. The total ranges from 0 to 42, with higher scores indicating more severe symptoms. Change is calculated as the follow-up score minus baseline. |
Baseline and weeks 2 and 8
|
|
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) Score
Tidsramme: Baseline and weeks 2, 4, and 8
|
Participants complete the disease-specific questionnaire about how chronic urticaria affected their lives in the preceding two weeks. Higher scores indicate greater impairment. Change is calculated as the follow-up score minus baseline. |
Baseline and weeks 2, 4, and 8
|
|
Change From Baseline in Serum Total Immunoglobulin E (IgE)
Tidsramme: Baseline and week 4
|
Serum total IgE is measured by enzyme-linked immunosorbent assay (ELISA) and reported in IU/mL. Change is calculated as the week 4 concentration minus baseline. |
Baseline and week 4
|
|
Proportion of Participants With Adverse Events
Tidsramme: From baseline through week 8
|
The study records adverse events and serious adverse events in each group during treatment and follow-up. Event severity is graded using the protocol-specified CTCAE criteria. |
From baseline through week 8
|
|
Proportion of Participants Reporting Recurrence or Flare of Urticaria Symptoms
Tidsramme: Weeks 4 through 8
|
Participants are contacted by telephone at week 8 using a standardized script to determine whether symptoms returned or flared during the post-treatment follow-up. |
Weeks 4 through 8
|
|
Number of Rescue Cetirizine Tablets Used
Tidsramme: From baseline through week 4
|
The total number of additional cetirizine tablets taken for symptom relief beyond the scheduled background dose is compared between groups. |
From baseline through week 4
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Association of Baseline UAS7, Serum Total IgE, and Disease Duration With UAS7 at Week 4
Tidsramme: Baseline and week 4
|
A multivariable linear regression will estimate the association of each baseline factor with week 4 UAS7, adjusting for study group and site. |
Baseline and week 4
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Sang Thanh Do, MD, MSc, University of Medicine and Pharmacy at Ho Chi Minh City
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Kronisk sygdom
- Sygdomsegenskaber
- Sygdomme i immunsystemet
- Overfølsomhed, Øjeblikkelig
- Overfølsomhed
- Hudsygdomme
- Nældefeber
- Hudsygdomme, vaskulære
- Patologiske tilstande, tegn og symptomer
- Hud- og bindevævssygdomme
- Kronisk nældefeber
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Piperaziner
- Hydroxyzin
- Cetirizin
Andre undersøgelses-id-numre
- 4861/ĐHYD-HĐĐĐ
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .